AI Stock Memo: LMAT - LeMaitre Vascular - RankAlpha

LMAT

Rating neutralAI MemoPost-earnings T+3

LeMaitre Vascular

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

June 4 dividend payment and active buyback authorization are modest support, not a thesis reset • 2026-06-04

Expected move: +9%

Biggest risk

The bear case is that the stock still de-rated after the print: the prior baseline anchor was $117.39 on 2026-04-15 versus $107.91 on 2026-05-07, so the market did not reward the beat-and-better setup with a sustained re-rate. That suggests investors may be questioning how repeatable the pricing, manufacturing-efficiency, and Artegraft-driven upside really is across the remaining quarters.

Invalidation

Break below $94 or thesis failure.

What would change my mind?

The post-earnings bull case is that Q1 delivered a clean operating print: revenue rose 11%, EPS rose 42%, gross margin expanded 350 bps, and management nudged the profit outlook higher while maintaining the roughly $280mm full-year sales frame. Secondary post-print coverage also indicated EPS was slightly above consensus while revenue was roughly in line, which supports the view that margin and expense discipline were the main positive surprise.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$111

p=50%

Bull target

$125

p=25%

Bear target

$94

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 beat with better margin and EPS guidance needs to stabilize the post-print tape
2026 operating leverage still hinges on Artegraft, pricing, and manufacturing efficiency sustaining through the year
The post-earnings bull case is that Q1 delivered a clean operating print: revenue rose 11%, EPS rose 42%, gross margin expanded 350 bps, and management nudged the profit outlook higher while maintaining the roughly $280mm full-year sales frame.

BearKey bullets

Artegraft and international growth were important Q1 contributors; if those growth drivers normalize, the premium quality narrative could soften quickly.
Full-year revenue guidance was effectively maintained around $280mm, so the better earnings outlook leans heavily on pricing, manufacturing efficiencies, and opex discipline staying intact.
Post-earnings price action was weak relative to the positive print, implying multiple-compression risk even when results beat on EPS.

WatchKey bullets

June 4 dividend payment and active buyback authorization are modest support, not a thesis reset

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $111 (p=50%)

Bull/Bear spread: +22% / -8%

Vs latest close: Bull +22% · Base +9% · Bear -8%

Scenario probabilities

Bull Target: $125 (p=25%)Base Target: $111 (p=50%)Bear Target: $94 (p=25%)

Commentary

This is a real earnings-update run, not a SERP-only memo: the company 8-K/Exhibit 99.1 confirms a solid Q1 and somewhat better profit outlook. Even so, the setup remains a tentative monitoring view because deterministic priors remain negative, analyst follow-through is thin, direct peer support is limited, and the stock sat at $107.91 on 2026-05-07 versus the prior baseline price of $117.39 on 2026-04-15 despite the beat. Headline volume is elevated by earnings, but the market reaction argues investors want another quarter of proof before paying up again.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 beat with better margin and EPS guidance needs to stabilize the post-print tape
2026 operating leverage still hinges on Artegraft, pricing, and manufacturing efficiency sustaining through the year

Scenarios

Bull Target (Scenario probability)

$125 / p=25% prob

Base Target (Scenario probability)

$111 / p=50% prob

Bear Target (Scenario probability)

$94 / p=25% prob

Price $102 as of 2026-07-30

Nearest Scenario: Bear (∆ 8%)

Targets vs latest close: Bull +22% · Base +9% · Bear -8%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-04
June 4 dividend payment and active buyback authorization are modest support, not a thesis reset
The same May 5 release announced a $0.25/share quarterly dividend payable June 4, 2026, and reminded investors of the board-authorized $100.0mm repurchase program approved on February 19, 2026, running through February 18, 2027. These capital-allocation tools help downside support, but they do not by themselves resolve whether LMAT can hold a premium multiple after the recent de-rating [#8-K-2026-05-05].
Prob 95.00% • Move 2.00% • Priced-in 90.00%

Short-term Catalysts

Next few weeks

Q1 beat with better margin and EPS guidance needs to stabilize the post-print tape
2026-05-05
LeMaitre's May 5 earnings release reported Q1 sales of $66.6mm (+11%), gross margin of 72.7% (+350 bps), operating income of $17.8mm (+41%), EPS of $0.68 (+42%), and cash of $367.2mm. Management also guided Q2 sales to $70.5mm-$72.5mm and kept full-year sales at roughly $280mm while guiding full-year operating income to $77.6mm-$82.0mm and EPS to $2.93-$3.08, with commentary that higher ASPs, geographic expansion, and disciplined spending are driving leverage [#8-K-2026-05-05].
Prob 78% • Move 6% • Priced-in 72%

Long-term Catalysts

Months to a year

2026 operating leverage still hinges on Artegraft, pricing, and manufacturing efficiency sustaining through the year
2026-12-31
Management highlighted 36% Artegraft growth worldwide, record sales in grafts, valvulotomes, and carotid shunts, geographic records across EMEA, APAC, and the Americas, and gross-margin expansion from higher pricing and manufacturing efficiencies. That is supportive, but the stock still appears to need repeat execution across the rest of 2026 because the revenue outlook was only maintained while the market has already been treating LMAT as a premium growth medtech name [#8-K-2026-05-05].
Prob 61% • Move 11% • Priced-in 60%

Risks

Artegraft and international growth were important Q1 contributors; if those growth drivers normalize, the premium quality narrative could soften quickly.
Full-year revenue guidance was effectively maintained around $280mm, so the better earnings outlook leans heavily on pricing, manufacturing efficiencies, and opex discipline staying intact.
Post-earnings price action was weak relative to the positive print, implying multiple-compression risk even when results beat on EPS.
The peer set is generic and lacks enough direct operating comparators, so relative valuation evidence is weak and this should remain a monitoring view rather than a standard-conviction thesis.

Peers

Symbol	Summary
BSX	Boston Scientific is only a broad cardiovascular-device benchmark, not a direct vascular-surgery pure-play. Its scale and diversification mainly show that LMAT's narrower vascular-surgeon channel deserves a higher execution discount than a larger medtech platform.
EW	Edwards is another broad cardiovascular-device reference rather than a close operating comp. The comparison is useful only for quality and margin expectations, while LMAT's smaller scale and more concentrated product portfolio make direct valuation read-through limited.
HAE	Haemonetics is closer on market cap but still a loose health-care equipment comparator. Its inclusion should be treated as a size and medtech-profitability cross-check, not as evidence that LMAT has a directly comparable public peer set.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08